Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Rare Disease Treatment Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Originator Drugs
  • 1.4.3 Generic Drugs
• 1.5 Market by Application
  • 1.5.1 Global Rare Disease Treatment Market Share by Application (2014-2025)
  • 1.5.2 Hospital Pharmacies
  • 1.5.3 Specialty Pharmacies
  • 1.5.4 Retail Pharmacies
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Rare Disease Treatment Market Size
• 2.2 Rare Disease Treatment Growth Trends by Regions
  • 2.2.1 Rare Disease Treatment Market Size by Regions (2014-2025)
  • 2.2.2 Rare Disease Treatment Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Opportunities

3 Market Share by Key Players

• 3.1 Rare Disease Treatment Market Size by Manufacturers
  • 3.1.1 Global Rare Disease Treatment Revenue by Manufacturers (2014-2019)
  • 3.1.2 Global Rare Disease Treatment Revenue Market Share by Manufacturers (2014-2019)
  • 3.1.3 Global Rare Disease Treatment Market Concentration Ratio (CR5 and HHI)
• 3.2 Rare Disease Treatment Key Players Head office and Area Served
• 3.3 Key Players Rare Disease Treatment Product/Solution/Service
• 3.4 Date of Enter into Rare Disease Treatment Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Rare Disease Treatment Market Size by Type (2014-2019)
• 4.2 Global Rare Disease Treatment Market Size by Application (2014-2019)

5 United States

• 5.1 United States Rare Disease Treatment Market Size (2014-2019)
• 5.2 Rare Disease Treatment Key Players in United States
• 5.3 United States Rare Disease Treatment Market Size by Type
• 5.4 United States Rare Disease Treatment Market Size by Application

6 Europe

• 6.1 Europe Rare Disease Treatment Market Size (2014-2019)
• 6.2 Rare Disease Treatment Key Players in Europe
• 6.3 Europe Rare Disease Treatment Market Size by Type
• 6.4 Europe Rare Disease Treatment Market Size by Application

7 China

• 7.1 China Rare Disease Treatment Market Size (2014-2019)
• 7.2 Rare Disease Treatment Key Players in China
• 7.3 China Rare Disease Treatment Market Size by Type
• 7.4 China Rare Disease Treatment Market Size by Application

8 Japan

• 8.1 Japan Rare Disease Treatment Market Size (2014-2019)
• 8.2 Rare Disease Treatment Key Players in Japan
• 8.3 Japan Rare Disease Treatment Market Size by Type
• 8.4 Japan Rare Disease Treatment Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Rare Disease Treatment Market Size (2014-2019)
• 9.2 Rare Disease Treatment Key Players in Southeast Asia
• 9.3 Southeast Asia Rare Disease Treatment Market Size by Type
• 9.4 Southeast Asia Rare Disease Treatment Market Size by Application

10 India

• 10.1 India Rare Disease Treatment Market Size (2014-2019)
• 10.2 Rare Disease Treatment Key Players in India
• 10.3 India Rare Disease Treatment Market Size by Type
• 10.4 India Rare Disease Treatment Market Size by Application

11 Central & South America

• 11.1 Central & South America Rare Disease Treatment Market Size (2014-2019)
• 11.2 Rare Disease Treatment Key Players in Central & South America
• 11.3 Central & South America Rare Disease Treatment Market Size by Type
• 11.4 Central & South America Rare Disease Treatment Market Size by Application

12 International Players Profiles

• 12.1 Novartis
  • 12.1.1 Novartis Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Rare Disease Treatment Introduction
  • 12.1.4 Novartis Revenue in Rare Disease Treatment Business (2014-2019)
  • 12.1.5 Novartis Recent Development
• 12.2 Pfizer
  • 12.2.1 Pfizer Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Rare Disease Treatment Introduction
  • 12.2.4 Pfizer Revenue in Rare Disease Treatment Business (2014-2019)
  • 12.2.5 Pfizer Recent Development
• 12.3 F. Hoffmann-La Roche
  • 12.3.1 F. Hoffmann-La Roche Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Rare Disease Treatment Introduction
  • 12.3.4 F. Hoffmann-La Roche Revenue in Rare Disease Treatment Business (2014-2019)
  • 12.3.5 F. Hoffmann-La Roche Recent Development
• 12.4 Celgene
  • 12.4.1 Celgene Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Rare Disease Treatment Introduction
  • 12.4.4 Celgene Revenue in Rare Disease Treatment Business (2014-2019)
  • 12.4.5 Celgene Recent Development
• 12.5 AbbVie
  • 12.5.1 AbbVie Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Rare Disease Treatment Introduction
  • 12.5.4 AbbVie Revenue in Rare Disease Treatment Business (2014-2019)
  • 12.5.5 AbbVie Recent Development
• 12.6 Johnson & Johnson
  • 12.6.1 Johnson & Johnson Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Rare Disease Treatment Introduction
  • 12.6.4 Johnson & Johnson Revenue in Rare Disease Treatment Business (2014-2019)
  • 12.6.5 Johnson & Johnson Recent Development
• 12.7 Shire
  • 12.7.1 Shire Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Rare Disease Treatment Introduction
  • 12.7.4 Shire Revenue in Rare Disease Treatment Business (2014-2019)
  • 12.7.5 Shire Recent Development
• 12.8 Alexion
  • 12.8.1 Alexion Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Rare Disease Treatment Introduction
  • 12.8.4 Alexion Revenue in Rare Disease Treatment Business (2014-2019)
  • 12.8.5 Alexion Recent Development
• 12.9 Novo Nordisk
  • 12.9.1 Novo Nordisk Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Rare Disease Treatment Introduction
  • 12.9.4 Novo Nordisk Revenue in Rare Disease Treatment Business (2014-2019)
  • 12.9.5 Novo Nordisk Recent Development
• 12.10 Sanofi
  • 12.10.1 Sanofi Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Rare Disease Treatment Introduction
  • 12.10.4 Sanofi Revenue in Rare Disease Treatment Business (2014-2019)
  • 12.10.5 Sanofi Recent Development
• 12.11 Bayer
• 12.12 Amgen
• 12.13 Allergan
• 12.14 Eisai
• 12.15 Bristol-Myers Squibb
• 12.16 Merck
• 12.17 Vertex Pharmaceuticals
• 12.18 Baxter
• 12.19 BioMarin
• 12.20 Teva Pharmaceutical Industries

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer

A rare disease is any disease that affects a small percentage of the population.
Most rare diseases are genetic and thus are present throughout the person's entire life, even if symptoms do not immediately appear.
In 2018, the global Rare Disease Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Rare Disease Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Rare Disease Treatment development in United States, Europe and China.

The key players covered in this study
Novartis
Pfizer
F. Hoffmann-La Roche
Celgene
AbbVie
Johnson & Johnson
Shire
Alexion
Novo Nordisk
Sanofi
Bayer
Amgen
Allergan
Eisai
Bristol-Myers Squibb
Merck
Vertex Pharmaceuticals
Baxter
BioMarin
Teva Pharmaceutical Industries

Market segment by Type, the product can be split into
Originator Drugs
Generic Drugs

Market segment by Application, split into
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Rare Disease Treatment status, future forecast, growth opportunity, key market and key players.
To present the Rare Disease Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Rare Disease Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.